Kristin Brooks01.28.14
Development and economic pressures continue to reign over pharma and biopharma firms, and as such, compels them to outsource some of their R&D activities, including discovery research — an area that previously was often kept in-house. The preclinical market has seen a relatively steady stream of work in expanded service areas, which offers the potential for further growth as specialized services and technologies continue to improve the compound selection process and outcomes.
Jean Pierre Wery, president of Crown Bioscience, a drug discovery and development service provider specializing in translational platforms dedicated to the therapeutic areas of oncology and metabolic disease, provides his perspective on the preclinical market, and discusses the growth of translational technologies, stability of drug discovery activities, as well as near term-expectations. －KB
Contract Pharma: Are there any notable trends in the preclinical space?
Jean Pierre Wery: It used to be that only specific preclinical activities, such as chemical synthesis of intermediat
Jean Pierre Wery, president of Crown Bioscience, a drug discovery and development service provider specializing in translational platforms dedicated to the therapeutic areas of oncology and metabolic disease, provides his perspective on the preclinical market, and discusses the growth of translational technologies, stability of drug discovery activities, as well as near term-expectations. －KB
Contract Pharma: Are there any notable trends in the preclinical space?
Jean Pierre Wery: It used to be that only specific preclinical activities, such as chemical synthesis of intermediat
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
